---
layout: default
title: Icatibant
description: "Icatibant 的老藥新用潛力分析。最高證據等級 L1，包含 7 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 高證據等級 (L1-L2)
nav_order: 85
evidence_level: L1
indication_count: 7
---

# Icatibant

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L1</strong> | 預測適應症: <strong>7</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Icatibant：從遺傳性血管性水腫到 C1 Inhibitor Deficiency

## 一句話總結

<p class="key-answer" data-question="Icatibant 可以用於治療什麼新適應症？">
Icatibant 原本用於遺傳性血管性水腫(HAE)急性發作的症狀治療。
TxGNN 模型預測它可能對 **C1 Inhibitor Deficiency** 有效，
目前有 **22 項臨床試驗** 和 **13 篇文獻** 支持這個方向，證據充足。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 遺傳性血管性水腫(HAE)急性發作症狀治療 |
| 預測新適應症 | C1 inhibitor deficiency、hereditary angioedema with C1Inh deficiency、serpinopathy with toxic serpin polymerization、hereditary angioedema、pseudo-von Willebrand disease、primary release disorder of platelets、immune-mediated necrotizing myopathy |
| TxGNN 預測分數 | 99.99% |
| 證據等級 | L1 |
| 台灣上市 | 已上市 |
| 許可證數 | 3 張 |
| 建議決策 | Proceed |






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. C1 inhibitor deficiency</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Icatibant 是一種緩激肽 B2 受體拮抗劑(Bradykinin B2 Receptor Antagonist)，透過阻斷緩激肽的作用來減少血管通透性增加所導致的水腫。在 C1 酯酶抑制劑缺乏的情況下，血漿緩激肽系統會異常活化，產生過量的緩激肽，進而導致血管性水腫。</p>

<p>這個預測在機轉上高度合理，因為：</p>
<ol>
<li>C1 Inhibitor Deficiency 是導致遺傳性血管性水腫的根本病因</li>
<li>Icatibant 直接阻斷緩激肽介導的血管通透性增加</li>
<li>此適應症與原核准適應症(HAE急性發作)在病理生理學上完全一致</li>
</ol>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01457430" target="_blank">NCT01457430</a></td><td>PHASE4</td><td>COMPLETED</td><td>19</td><td>Open Label, Multicenter Study to Evaluate Efficacy, Safety and Tolerability of a...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00997204" target="_blank">NCT00997204</a></td><td>PHASE3</td><td>COMPLETED</td><td>151</td><td>Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenienc...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00912093" target="_blank">NCT00912093</a></td><td>PHASE3</td><td>COMPLETED</td><td>98</td><td>A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Ic...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03888755" target="_blank">NCT03888755</a></td><td>PHASE3</td><td>COMPLETED</td><td>8</td><td>An Open-Label Study of Icatibant in Japanese Subjects With Acute Attacks of Here...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00500656" target="_blank">NCT00500656</a></td><td>PHASE3</td><td>COMPLETED</td><td>85</td><td>Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subc...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02584959" target="_blank">NCT02584959</a></td><td>PHASE3</td><td>COMPLETED</td><td>75</td><td>A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-seque...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04208412" target="_blank">NCT04208412</a></td><td>PHASE2</td><td>COMPLETED</td><td>84</td><td>A Randomized, Double-blind, Placebo-controlled, Phase II, Cross-over Clinical Tr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01034969" target="_blank">NCT01034969</a></td><td>N/A</td><td>COMPLETED</td><td>1761</td><td>Icatibant Outcome Survey (IOS) Registry</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05509569" target="_blank">NCT05509569</a></td><td>N/A</td><td>COMPLETED</td><td>32</td><td>Specified Drug Use Surveillance of FIRAZYR Subcutaneous Injection 30mg Syringe f...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05489640" target="_blank">NCT05489640</a></td><td>N/A</td><td>COMPLETED</td><td>85</td><td>A Real-World Study to Determine Patient Characteristics, Treatment Patterns, Cli...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07290855" target="_blank">NCT07290855</a></td><td>PHASE4</td><td>COMPLETED</td><td>5</td><td>A Phase IV Clinical Study of Evaluating the Safety and Efficacy of Icatibant Inj...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03240133" target="_blank">NCT03240133</a></td><td>PHASE2</td><td>COMPLETED</td><td>58</td><td>A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study to Evaluate ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04057131" target="_blank">NCT04057131</a></td><td>N/A</td><td>COMPLETED</td><td>179</td><td>FIRAZYR General Drug Use-Results Survey (Japan)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04654351" target="_blank">NCT04654351</a></td><td>PHASE3</td><td>COMPLETED</td><td>2</td><td>A Multicenter, Open-Label, Non-randomized Phase 3 Study to Assess the Safety, Ef...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01386658" target="_blank">NCT01386658</a></td><td>PHASE3</td><td>COMPLETED</td><td>32</td><td>A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04898309" target="_blank">NCT04898309</a></td><td>PHASE2, PHASE3</td><td>WITHDRAWN</td><td>0</td><td>A Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of GNR...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02870972" target="_blank">NCT02870972</a></td><td>PHASE2</td><td>COMPLETED</td><td>75</td><td>A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Stu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06587464" target="_blank">NCT06587464</a></td><td>N/A</td><td>COMPLETED</td><td>19</td><td>Exploring Symptom Profile and Treatment Patterns in Korean HAE Patients Using Di...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05460325" target="_blank">NCT05460325</a></td><td>PHASE3</td><td>COMPLETED</td><td>20</td><td>A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and E...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06346899" target="_blank">NCT06346899</a></td><td>N/A</td><td>COMPLETED</td><td>115</td><td>The Real-World Effectiveness and Safety of Lanadelumab (Takhzyro) and Icatibant ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00097695" target="_blank">NCT00097695</a></td><td>PHASE3</td><td>COMPLETED</td><td>84</td><td>Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneou...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02045264" target="_blank">NCT02045264</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>An Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tole...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07009262" target="_blank">NCT07009262</a></td><td>N/A</td><td>COMPLETED</td><td>88</td><td>A Prospective, Non-interventional Study in Patients With Type I or II Hereditary...</td></tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29757016/" target="_blank">29757016</a></td><td>2018</td><td>Article</td><td>Expert review of clinical immu</td><td>Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficienc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28687105/" target="_blank">28687105</a></td><td>2017</td><td>Article</td><td>Immunology and allergy clinics</td><td>Acquired C1 Inhibitor Deficiency.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23420425/" target="_blank">23420425</a></td><td>2013</td><td>Article</td><td>Pneumonologia i alergologia po</td><td>[Administration of conestat alfa, human C1 esterase inhibitor and icatibant in t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24925394/" target="_blank">24925394</a></td><td>2014</td><td>Article</td><td>Chemical immunology and allerg</td><td>Bradykinin-mediated diseases.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35662289/" target="_blank">35662289</a></td><td>2022</td><td>Article</td><td>Clinical and experimental alle</td><td>Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryng...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32753245/" target="_blank">32753245</a></td><td>2020</td><td>Article</td><td>La Revue de medecine interne</td><td>[Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for d...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26842379/" target="_blank">26842379</a></td><td>2016</td><td>Article</td><td>Polskie Archiwum Medycyny Wewn</td><td>Bradykinin-mediated angioedema.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37146882/" target="_blank">37146882</a></td><td>2023</td><td>Article</td><td>The journal of allergy and cli</td><td>A National Survey of Hereditary Angioedema and Acquired C1 Inhibitor Deficiency ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37716525/" target="_blank">37716525</a></td><td>2023</td><td>Article</td><td>The journal of allergy and cli</td><td>Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)-A Bicenter Retro...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33602658/" target="_blank">33602658</a></td><td>2021</td><td>Article</td><td>Journal of investigational all</td><td>Treatment of Hereditary Angioedema.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20667117/" target="_blank">20667117</a></td><td>2010</td><td>Article</td><td>Allergy, asthma, and clinical </td><td>Acquired angioedema.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28284781/" target="_blank">28284781</a></td><td>2017</td><td>Article</td><td>The journal of allergy and cli</td><td>Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inh...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31690390/" target="_blank">31690390</a></td><td>2019</td><td>Article</td><td>Allergy and asthma proceedings</td><td>Hereditary and acquired angioedema.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33472202/" target="_blank">33472202</a></td><td>2021</td><td>Article</td><td>International archives of alle</td><td>Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features,...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26972189/" target="_blank">26972189</a></td><td>2016</td><td>Article</td><td>Journal der Deutschen Dermatol</td><td>Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26106828/" target="_blank">26106828</a></td><td>2015</td><td>Article</td><td>Current opinion in allergy and</td><td>Diagnostic and therapeutic management of hereditary angioedema due to C1-inhibit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37898409/" target="_blank">37898409</a></td><td>2024</td><td>Article</td><td>The Journal of allergy and cli</td><td>Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficien...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22686628/" target="_blank">22686628</a></td><td>2012</td><td>Article</td><td>Allergy</td><td>Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observati...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30280305/" target="_blank">30280305</a></td><td>2018</td><td>Article</td><td>Journal of clinical immunology</td><td>Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inh...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35871284/" target="_blank">35871284</a></td><td>2023</td><td>Article</td><td>Journal of clinical pharmacolo</td><td>Large Predominance of Off-Label Prescriptions of C1-Inhibitor Concentrates and I...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. serpinopathy with toxic serpin polymerization</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pseudo-von Willebrand disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. primary release disorder of platelets</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.14%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. immune-mediated necrotizing myopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.06%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. antisynthetase syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.02%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. Glanzmann thrombasthenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.00%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 衛部罕藥製字第000021號 | 益康倍注射劑 | 注射液劑 | C1酯酶抑制劑不足的成人、青少年及2歲以上兒童 HAE 急性發作症狀治療 |
| 衛部罕藥輸字第000066號 | 凡得適注射劑30毫克 | 注射液劑 | C1酯酶抑制劑不足的成人、青少年及2歲以上兒童 HAE 急性發作症狀治療 |

## 安全性考量

- **藥物交互作用**：
  - **主要交互作用**：ACE 抑制劑類藥物(Benazepril、Captopril、Enalapril、Lisinopril、Perindopril、Trandolapril、Moexipril)（中度）
  - **機轉說明**：Icatibant 可能降低 ACE 抑制劑的降壓效果

- **常見副作用**：注射部位反應（紅斑、腫脹）

## 結論與下一步

**決策：Proceed**

**理由：**
此預測與原核准適應症高度一致。Icatibant 已獲核准用於 C1 酯酶抑制劑缺乏導致的 HAE 急性發作，而 C1 Inhibitor Deficiency 正是此疾病的根本病因。大量臨床試驗和文獻均支持其療效與安全性。

**目前狀態：**
- 已有充分的臨床證據支持
- 台灣已有核准適應症涵蓋此用途
- 可直接應用於臨床實踐


---

## 相關藥物報告

- [Anastrozole]({{ "/drugs/anastrozole/" | relative_url }}) - 證據等級 L1
- [Temozolomide]({{ "/drugs/temozolomide/" | relative_url }}) - 證據等級 L1
- [Ipratropium]({{ "/drugs/ipratropium/" | relative_url }}) - 證據等級 L1
- [Docetaxel]({{ "/drugs/docetaxel/" | relative_url }}) - 證據等級 L1
- [Naftifine]({{ "/drugs/naftifine/" | relative_url }}) - 證據等級 L1

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Icatibant老藥新用驗證報告. https://twtxgnn.yao.care/drugs/icatibant/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_icatibant,
  title = {Icatibant老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/icatibant/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
